Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Pharmacokinetic Drug-drug Interaction of CKD-330 and D086

Phase 1

Completed

Conditions: Hypertension
Hyperlipidemias

Interventions: Drug: CKD-330
Drug: D086
Drug: CKD-330 + D086

First Posted Date: 2017-01-11

Last Posted Date: 2017-07-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 83

Registration Number: NCT03017950

Locations: 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of

To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors

Phase 2

Completed

Conditions: Dyslipidemias

Interventions: Drug: Atorvastatin 20 mg + CKD-519 50 mg
Drug: Atorvastatin 20 mg + CKD-519 200 mg
Drug: Atorvastatin 20mg
Drug: Rosuvastatin 10 mg
Drug: Atorvastatin 20 mg + CKD-519 100 mg
Drug: Rosuvastatin 10 mg + CKD-519 100 mg

First Posted Date: 2016-11-30

Last Posted Date: 2018-11-06

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 62

Registration Number: NCT02977065

Locations: 🇦🇺
Not provided, Adelaide, Australia

Study to Investigate the Influence of CKD-519 on 24-h Ambulatory Blood Pressure in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CKD-519 200mg
Drug: Placebo

First Posted Date: 2016-09-28

Last Posted Date: 2017-02-23

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 32

Registration Number: NCT02916901

Locations: 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu 120-752, Korea, Republic of

Study to Investigate the Effects of Food on the Pharmacokinetics/Pharmacodynamics of CKD-519

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CKD-519 100mg
Drug: CKD-519 200mg

First Posted Date: 2016-09-09

Last Posted Date: 2017-02-23

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 48

Registration Number: NCT02894541

Locations: 🇰🇷
Korea university medical center, Seoul, Sungbuk-gu, Korea, Republic of

Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin

Phase 1

Conditions: Diabetes Mellitus, Type II

Interventions: Drug: Empagliflozin 25mg
Drug: Lobeglitazone 0.5mg
Drug: Empagliflozin 25mg/Lobeglitazone 0.5mg

First Posted Date: 2016-08-03

Last Posted Date: 2016-08-09

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT02854748

Locations: 🇰🇷
Dong A University Hospital, Seo-gu, Busan, Korea, Republic of

CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)

Phase 1

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: Januvia Tab. 100mg
Drug: Januvia Tab. 100mg + Duvie Tab. 0.5mg

First Posted Date: 2016-07-11

Last Posted Date: 2017-08-09

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 20

Registration Number: NCT02827890

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju-si, Korea, Republic of

CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)

Phase 1

Completed

Conditions: Diabetes Mellitus, Type II

Interventions: Drug: Duvie Tab. 0.5mg
Drug: Duvie Tab. 0.5mg + Januvia Tab. 100mg

First Posted Date: 2016-07-07

Last Posted Date: 2016-07-11

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 20

Registration Number: NCT02824874

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju-si, Korea, Republic of

Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - B

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: CKD-330 16/5mg - B
Drug: Candesartan 16mg and Amlodipine 5mg

First Posted Date: 2016-06-23

Last Posted Date: 2016-06-23

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 32

Registration Number: NCT02811731

Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet

Phase 3

Conditions: Chronic Hepatitis B

Interventions: Drug: viread
Drug: CKD-390

First Posted Date: 2016-06-20

Last Posted Date: 2016-06-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 158

Registration Number: NCT02805738

Locations: 🇰🇷
Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of
🇰🇷
Bundang Cha Medical Center, Bundang, Gyeonggi-do, Korea, Republic of
🇰🇷
Jeju National University Hospital, Jeju, Korea, Republic of

and more 17 locations

Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Candesartan 16mg and Amlodipine 5mg
Drug: CKD-330 16/5mg - A

First Posted Date: 2016-06-16

Last Posted Date: 2016-06-16

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 32

Registration Number: NCT02801526

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy